Utilities for advanced basal cell carcinoma

Shingler, S.L.; Garside, Jamie; Samanta, Kunal; Lear, John T.; Keohane, S.G.; Lloyd, Andrew

doi:10.3111/13696998.2013.800822

Cited by 18 publications

(29 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More recently, Shingler and colleagues 34 conducted a sponsored study to help derive TTO utility weightings for advanced BCC (aBCC), defined as BCC that has progressed to become life-threatening, unresectable, locally advanced or metastatic. 35 The study involved the construction of nine health states associated with aBCC through interviews with two dermatologists.…”

Section: Quality Of Life Utility Weightingsmentioning

confidence: 99%

Quality of life in non‐melanoma skin cancer

2014

View full text Add to dashboard Cite

Basal cell carcinoma and squamous cell carcinoma are the most common malignancies and are classified under the umbrella of non-melanoma skin cancer (NMSC). NMSC exerts a small but appreciable decrement in quality of life (QOL). The impact posed may arise from the tumour itself or as a result of treatment, and through symptoms, functional limitations, cosmetic burden and auxiliary considerations such as cost and disturbance to the activities of daily living. Researchers have evaluated this burden using a variety of outcome measures including generic, dermatology-specific and disease-specific instruments. The skin cancer index represents a promising disease-specific patient-reported outcome measure in this setting. To overcome some of the constraints inherent to disease-specific instruments, and to allow comparisons with other diseases, utility weightings have been developed. Utility weightings represent a cardinal measure for a specific health status and are established through methods such as the standard gamble, willingness-to-pay and time trade-off, and have also been employed to generate utility weightings for NMSC. Utilities are becoming increasingly important as a means of comparing health states across medicine and are of particular importance from a health-care policy perspective as they are used for resource allocation. The small but definite impact on the individual's QOL posed by NMSC should be a clinical consideration for physicians and it should be recognised by researchers as a potential outcome measure.

show abstract

Section: Quality Of Life Utility Weightingsmentioning

confidence: 99%

Quality of life in non‐melanoma skin cancer

2014

View full text Add to dashboard Cite

show abstract

“…Previous studies of societal utility values in Europe have used similar sample sizes to those included in this study. 24 Descriptive statistics were used to summarise socio-demographic data, with means and standard deviations (SD) for continuous data and percentages for categorical data. EQ-5D data was scored according to the developer's guidelines (EQ-5D-3L user guide).…”

Section: Discussionmentioning

confidence: 99%

Disutility Study for Adult Patients with Moderate to Severe Crohn’s Disease

Worbes-Cerezo

Nafees²,

Lloyd

et al. 2019

JHEOR

View full text Add to dashboard Cite

Background: Crohn’s disease (CD) treatments and associated adverse events (AEs) can be burdensome for patients. However, specific values which quantify the impact on health-related quality of life (HRQL) for economic evaluation are lacking. Objectives: This study aimed to elicit health utility values for AEs related to biologic treatment and surgical complications for CD in the UK. Methods: Health states were developed by literature review and interviews with CD patients (n=6) and gastroenterologists (n=3). Draft health states were validated in cognitive debrief interviews with patients (n=4) and gastroenterologists (n=2). Treatment AEs were described with moderate severe CD (reference state) and included hypersensitivity, injection site reactions, serious infection, lymphoma, and tuberculosis. Surgical complications were described following bowel surgery (reference state) and included anastomotic leak, wound infection, prolonged ileus/bowel obstruction, and intra-abdominal abscess. Health states were valued by 100 members of the general public who completed background questions, EQ-5D-3L, visual analogue scale rating task and time trade-off (TTO) interviews. Results: The mean TTO value for reference states ‘moderate to severe CD’ and ‘bowel surgery’ were 0.70 (SD=0.28) and 0.69 (SD=0.28). Participants rated lymphoma as the worst AE/surgical complication state (0.44, SD=0.37), followed by tuberculosis (0.47, SD=0.85) and anastomotic leak (0.48, SD=0.38). Values of other AE/surgical complication states ranged from 0.76 (hypersensitivity) to 0.56 (intra-abdominal abscess). Conclusions: This study provides utility estimates for AE and surgical complication health states not previously assessed in the context of CD. As new treatments are emerging, it is important to include these influences on quality of life in any economic evaluation of treatments.

show abstract

“…Exploratory studies into the physical and psychosocial impact of advanced BCCs are underway; however, the disease can be challenging to characterize, in part due to variable progression and rarity of the disease [18, 19]. Anecdotal evidence from our clinical experience suggests that aBCC patients are subject to significant physical and psychological burden.…”

Section: Economic Physical and Psychosocial Impact Of Advanced Bccsmentioning

confidence: 99%

“…Alternatively, muscle spasms or other side effects may limit the ability of patients to take the drug in the long term, and/or maintain a good quality of life despite disease stabilization. Patient-based instruments recently have been developed to better assess these endpoints [18, 19]. …”

Section: Role Of Smoothened Inhibitors In Advanced Bcc Treatmentmentioning

confidence: 99%

Advanced Basal Cell Carcinoma: Epidemiology and Therapeutic Innovations

2014

View full text Add to dashboard Cite

Advanced basal cell carcinomas are a subset of basal cell carcinomas that can be difficult to treat either due to their local invasiveness, proximity to vital structures, or metastasis. The incidence of all basal cell carcinoma is increasing in the United States, although it is not known whether advanced basal cell carcinomas (aBCCs) are also increasing. Recently, highly targeted therapy based on knowledge of the basal cell carcinoma pathogenesis has become available either commercially or through human clinical trials. These orally available drugs inhibit the Hedgehog signaling pathway, and lead to advanced basal cell carcinoma shrinkage that can enable preservation of adjacent vital organs. In this review, we outline the role of Hedgehog pathway inhibitors as well as other treatment modalities such as excision, radiotherapy and more traditional chemotherapy in treating advanced basal cell carcinomas. We also highlight current gaps in knowledge regarding the use and side effects of this targeted therapy.

show abstract

Utilities for advanced basal cell carcinoma

Cited by 18 publications

References 14 publications

Quality of life in non‐melanoma skin cancer

Quality of life in non‐melanoma skin cancer

Disutility Study for Adult Patients with Moderate to Severe Crohn’s Disease

Advanced Basal Cell Carcinoma: Epidemiology and Therapeutic Innovations

Contact Info

Product

Resources

About